Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis

Clin Cancer Res. 2004 Oct 1;10(19):6437-48. doi: 10.1158/1078-0432.CCR-04-0841.

Abstract

Purpose: To establish effective antitumor immunotherapy for esophageal cancer, we tried to identify an useful target antigen of esophageal cancer.

Experimental design: We did cDNA microarray analysis to find a novel candidate antigen, proliferation potential-related protein (PP-RP). We examined cytotoxicity against tumor cells in vitro and in vivo of CTLs specific to PP-RP established from esophageal cancer patients.

Results: In 26 esophageal cancer tissues, an average of relative ratio of the expression of the PP-RP mRNA in cancer cells versus adjacent normal esophageal tissues was 396.2. Immunohistochemical analysis revealed that, in 20 of the 22 esophageal cancer tissues, PP-RP protein was strongly expressed only in the cancer cells and not so in normal esophageal epithelial cells. PP-RP protein contains 10 epitopes recognized by HLA-A24-restricted CTLs. These CTLs, generated from HLA-A24-positive esophageal cancer patients, had cytotoxic activity against cancer cell lines positive for both PP-RP and HLA-A24. Furthermore, adoptive transfer of the PP-RP-specific CTL line inhibited the growth of a human esophageal cancer cell line engrafted in nude mice.

Conclusions: The expression of PP-RP in esophageal cancer cells was significantly higher than in normal cells, and the CTLs recognizing PP-RP killed tumor cells in vitro and also showed tumor rejection effects in a xenograft model. Therefore, PP-RP may prove to be an ideal tumor antigen useful for diagnosis and immunotherapy for patients with esophageal cancer. cDNA microarray analysis is a useful method to identify ideal tumor-associated antigens.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Animals
  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / immunology
  • Antigens, Neoplasm / pharmacology
  • Carrier Proteins / genetics*
  • Carrier Proteins / immunology
  • Carrier Proteins / pharmacology
  • Cell Line, Tumor
  • Cytotoxicity Tests, Immunologic / methods
  • DNA-Binding Proteins / genetics*
  • DNA-Binding Proteins / immunology
  • DNA-Binding Proteins / pharmacology
  • Esophageal Neoplasms / genetics
  • Esophageal Neoplasms / pathology
  • Esophageal Neoplasms / therapy*
  • Female
  • Gene Expression Regulation, Neoplastic
  • HLA-A Antigens / immunology
  • HLA-A24 Antigen
  • Humans
  • Immunotherapy / methods*
  • Immunotherapy, Adoptive / methods
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Middle Aged
  • Neoplasm, Residual / genetics
  • Neoplasm, Residual / pathology
  • Placenta / metabolism
  • Prognosis
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Survival Analysis
  • T-Lymphocytes, Cytotoxic / immunology
  • Testis / metabolism
  • Ubiquitin-Protein Ligases
  • Xenograft Model Antitumor Assays

Substances

  • Antigens, Neoplasm
  • Carrier Proteins
  • DNA-Binding Proteins
  • HLA-A Antigens
  • HLA-A24 Antigen
  • RNA, Messenger
  • RBBP6 protein, human
  • Ubiquitin-Protein Ligases